Thermo Fisher Prices $3.8B Senior Notes for Clario Financing (TMO)

Thermo Fisher Scientific Inc. (TMO) priced $3.8 billion in senior notes on February 10, 2026, to finance the acquisition of Clario, a U.S.-based digital health platform. The proceeds will be used to complete the previously announced acquisition, which is pending regulatory approvals. The company cited the funding as a strategic step to strengthen its global diagnostic and life sciences capabilities. The notes were sold at a yield of 4.5%, with the issue scheduled to mature in 2029.